{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:51:22Z","timestamp":1777906282266,"version":"3.51.4"},"reference-count":24,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Summary: Anti PD1\/PD-L1 agents, including pembrolizumab, have revolutionized the oncological treatment of different types of cancer, including non-small cell lung cancer. The most frequent complications associated with this type of treatment are mild and are located at the thyroid, pulmonary or hepatic level. Sarcoid like reaction and mesenteric panniculitis secondary to pembrolizumab treatment are two very rare adverse effects. We present the case of a patient with these complications. Purpose: the treatment of metastatic non-small cell lung cancer has undergone a major change in the last 10 years, largely due to the advent of immunotherapy. Anti PD1 agents such as pembrolizumab have increased the median survival of these patients from 13 to 26 months. Most frequent immunorelated side effects are hypothyroidism, pneumonitis or elevated liver enzymes. However, there are other adverse effects, including sarcoid-like reaction and mesenteric panniculitis, which should be known by the professionals involved in the diagnosis and treatment of this type of patient. We present the case of a 62-year-old man with a history of unresectable and non-irradiable stage IIIB epidermoid lung carcinoma with a PD-L1 expression of 30% in whom pembrolizumab was discontinued after 4 cycles due to immunorelated arthritis. One year later he consulted for severe abdominal pain. A PET-CT scan was performed, showing hilar lymphadenopathy and inflammation of abdominal mesenteric fat. A biopsy of lesions in both areas showed non-necrotizing granulomatous lymphadenitis in hilar adenopathy and patchy fibrosis of mesenteric fat. The picture was classified as sarcoidosis-like reaction and mesenteric panniculitis secondary to pembrolizumab. Anti-PD1 agents cause hyperactivation of the immune system through T-cell proliferation. Sarcoid-like reaction is a very rare complication that can mask progressive tumor disease. Awareness of immunorelated complications by oncologists, internists, and radiologists is important for an appropriate diagnostic approach and targeted test ordering.<\/jats:p>","DOI":"10.3390\/curroncol31110540","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:57:54Z","timestamp":1732172274000},"page":"7319-7329","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding?"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4606-2316","authenticated-orcid":false,"given":"Luis","family":"Posado-Dom\u00ednguez","sequence":"first","affiliation":[{"name":"Medical Oncology Department, University Hospital of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Escribano-Iglesias","sequence":"additional","affiliation":[{"name":"Radiodiagnosis Service, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Bellido-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johana Gabriela","family":"Le\u00f3n-Gil","sequence":"additional","affiliation":[{"name":"Pathology Department, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"G\u00f3mez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Pathology Department, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6824-965X","authenticated-orcid":false,"given":"Felipe","family":"G\u00f3mez-Caminero L\u00f3pez","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Nuclear Medicine Service, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3357-3341","authenticated-orcid":false,"given":"Mar\u00eda","family":"Mart\u00edn-Galache","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra M.","family":"In\u00e9s-Revuelta","sequence":"additional","affiliation":[{"name":"Internal Medicine Service, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Fonseca-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"ref_1","unstructured":"Rozman, C., and Cardellach, F. (2020). Farreras Rozman Medicina Interna Decimonovena Edici\u00f3n Volumen 1, Elsevier. [19th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.ejrad.2013.06.023","article-title":"Is mesenteric panniculitis truely a paraneoplastic phenomenon? A matched pair analysis","volume":"82","author":"Albrecht","year":"2013","journal-title":"Eur. J. Radiol."},{"key":"ref_3","first-page":"700","article-title":"Mesenteric panniculitis","volume":"148","author":"Khachaturian","year":"1988","journal-title":"West. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2214\/ajr.174.2.1740427","article-title":"CT evaluation of mesenteric panniculitis: Prevalence and associated diseases","volume":"174","author":"Daskalogiannaki","year":"2000","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.gastrohep.2013.06.010","article-title":"Paniculitis mesent\u00e9rica col\u00f3nica","volume":"37","author":"Carbonell","year":"2014","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1007\/s00432-023-04802-2","article-title":"Sclerosing mesenteritis following immune checkpoint inhibitor therapy","volume":"149","author":"Kuang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_7","first-page":"240","article-title":"Paniculitis mesent\u00e9rica: Presentaci\u00f3n de 10 casos","volume":"99","year":"2007","journal-title":"Rev. Esp. Enfermedades Dig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/codi.13154","article-title":"Malignancy and mesenteric panniculitis","volume":"18","author":"Cross","year":"2016","journal-title":"Color. Dis."},{"key":"ref_9","unstructured":"(2024, September 07). Cohort Study of Mesenteric Panniculitis and Its Relationship to Malignancy\u2014Buchwald\u20142016\u2014BJS (British Journal of Surgery)\u2014Wiley Online Library. Available online: https:\/\/bjssjournals.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/bjs.10229."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non\u2013Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.05.020","article-title":"New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?","volume":"66","author":"Garrido","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ferini, G., Zagardo, V., Boncoraglio, A., Aiello, M.M., and Pontoriero, A. (2024). Leptomeningeal tumor spread or immune checkpoint inhibitor-related encephalitis\/(poli-)neuritis? An unsolved dilemma in a patient on pembrolizumab for a history of brain metastases from lung adenocarcinoma. Acta Neurol. Belg.","DOI":"10.1007\/s13760-023-02462-0"},{"key":"ref_13","first-page":"E22","article-title":"Pembrolizumab-induced lobular panniculitis in the setting of metastatic melanoma","volume":"105","author":"Peterman","year":"2020","journal-title":"Cutis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.mayocp.2020.08.037","article-title":"A Rare Case of Pembrolizumab-Associated Granulomatous Panniculitis","volume":"95","author":"Rozenova","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clindermatol.2007.03.010","article-title":"Sarcoidosis and malignancy","volume":"25","author":"Cohen","year":"2007","journal-title":"Clin. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00000658-196506000-00006","article-title":"Mesenteric Panniculitis: Review of 27 Cases","volume":"161","author":"Ogden","year":"1965","journal-title":"Ann. Surg."},{"key":"ref_18","first-page":"505","article-title":"Mesenteric panniculitis in the differential diagnosis of abdominal pain","volume":"88","year":"1996","journal-title":"Rev. Esp. Enfermedades Dig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10140-024-02255-9","article-title":"Association between mesenteric panniculitis and urolithiasis","volume":"31","author":"Dadkhah","year":"2024","journal-title":"Emerg. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clinimag.2021.05.006","article-title":"Association between mesenteric panniculitis and non-neoplastic disorders","volume":"79","author":"Gunes","year":"2021","journal-title":"Clin. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1259\/bjr.75.892.750378","article-title":"Mesenteric panniculitis associated with abdominal tuberculous lymphadenitis: A case report and review of the literature","volume":"75","author":"Ege","year":"2002","journal-title":"Br. J. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.dld.2022.06.017","article-title":"Mesenteric panniculitis is associated with cardiovascular risk-factors: A case-control study","volume":"54","author":"Schweistein","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1138-3593(09)71369-3","article-title":"S\u00edndrome de L\u00f6fgren. A prop\u00f3sito de un caso","volume":"35","author":"Kurnat","year":"2009","journal-title":"SEMERGEN Med. Fam."},{"key":"ref_24","first-page":"592","article-title":"Sarcoidosis-like Granulomatous Reaction Associated With Pembrolizumab Immunotherapy","volume":"54","year":"2018","journal-title":"Arch. Bronconeumol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:34:21Z","timestamp":1760114061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["curroncol31110540"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31110540","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]}}}